Switchpoint Bio, a Helsinki-based biotechnology startup, has emerged from stealth mode following a €4.75 million pre-seed funding round led by Treehouse Delmar Investments. The capital injection will support the company’s development of a blood-based epigenomic platform designed to provide pharmaceutical companies with new insights into disease mechanisms and treatment responses.
The newly founded company, established in 2025, operates at the intersection of epigenomics and artificial intelligence, focusing on translating complex biological data into actionable evidence for drug developers. The platform leverages blood-based biomarkers to offer what the company describes as a scalable approach to understanding disease and measuring the effects of therapeutic interventions.
Deployment of Capital
Switchpoint Bio plans to allocate the fresh funding across several strategic priorities. The investment will support continued clinical validation and industry partnerships, while also enabling the expansion of the company’s biobank datasets—critical resources for training and refining epigenomic algorithms. The capital will additionally fund further development of the core epigenomic and artificial intelligence platform, with hiring plans targeting both Helsinki and Cambridge to strengthen the scientific and technical teams.
Dave Proctor, representing lead investor Treehouse Delmar Investments, commented on the backing, stating: “We take a long-term view, backing science we believe can genuinely change how disease is understood and treated. Switchpoint Bio brings together exceptional scientific talent with a real path to turning breakthrough biology into evidence that helps patients, and we’re proud to support that work.”
Positioning in the TechBio Landscape
The emergence of Switchpoint Bio reflects growing interest in epigenomic approaches within the European healthtech ecosystem. Epigenomics—the study of chemical modifications to DNA and associated proteins that influence gene expression without altering the underlying genetic sequence—has gained prominence as a potential tool for understanding disease heterogeneity and predicting treatment responses. Blood-based biomarkers represent a particularly attractive avenue for pharmaceutical development, offering non-invasive methods to monitor patient populations during clinical trials.
The company’s dual-hub strategy, maintaining operations in both Helsinki and Cambridge, positions it to draw on Nordic biotech expertise while accessing the established life sciences infrastructure of the UK’s scientific corridor.
Switchpoint Bio’s entry into the market occurs amid accelerating investment in AI-driven drug discovery and development across Europe. The continent has witnessed sustained funding activity in companies combining machine learning capabilities with biological datasets, particularly those addressing unmet needs in disease diagnostics and patient stratification.
The startup’s focus on providing pharmaceutical companies with scalable epigenomic insights addresses a recognized gap in current drug development workflows, where understanding disease biology at the molecular level remains a significant challenge for many therapeutic programs.